

# INTRAVITREAL BEVACIZUMAB TREATMENT OF CHORIOIDITIS TO AGE-RELATED MACULAR DEGENERATION

Retina

26, 383-390

DOI: [10.1097/01.iae.0000238561.99283.0e](https://doi.org/10.1097/01.iae.0000238561.99283.0e)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration Twelve-Week Results of an Uncontrolled Open-Label Clinical Study. <i>Ophthalmology</i> , 2005, 112, 1035-1047.e9.	2.5	626
2	Intravitreal Avastin: The Low Cost Alternative to Lucentis?. <i>American Journal of Ophthalmology</i> , 2006, 142, 141-143.	1.7	117
3	Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2006, 113, 2002-2011.e2.	2.5	187
4	Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation Study. , 2006, 47, 4569.		158
5	Age-related macular degeneration: an overview and update. <i>Therapy: Open Access in Clinical Medicine</i> , 2006, 3, 417-424.	0.2	1
6	TREATMENT OF CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA WITH INTRAVITREAL BEVACIZUMAB. <i>Retina</i> , 2006, 26, 960-963.	1.0	82
7	Expanding Treatment Options in Age-related Macular Degeneration. <i>International Ophthalmology Clinics</i> , 2006, 46, 123-129.	0.3	9
8	Avastin and New Treatments for AMD: Where Are We?. <i>Retina</i> , 2006, 26, 853-858.	1.0	32
9	SHORT-TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2006, 26, 495-511.	1.0	484
10	Ranibizumab. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 815-816.	21.5	31
12	Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2006, 245, 68-73.	1.0	112
14	Opaque coating of an intraocular lens and regression of iris neovascularization following injection of triamcinolone acetonide into the anterior chamber. <i>Clinical and Experimental Ophthalmology</i> , 2006, 34, 803-805.	1.3	3
15	Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). <i>Clinical and Experimental Ophthalmology</i> , 2006, 34, 802-803.	1.3	40
16	Evolving European guidance on the medical management of neovascular age related macular degeneration. <i>British Journal of Ophthalmology</i> , 2006, 90, 1188-1196.	2.1	62
17	The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. <i>British Journal of Ophthalmology</i> , 2006, 90, 1344-1349.	2.1	502
18	Some ethical considerations for the "off-label" use of drugs such as Avastin. <i>British Journal of Ophthalmology</i> , 2006, 90, 1218-1219.	2.1	13
19	Is intravitreal bevacizumab (Avastin) safe?. <i>British Journal of Ophthalmology</i> , 2006, 90, 1333-1334.	2.1	25
20	Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. <i>British Journal of Ophthalmology</i> , 2007, 91, 1716-1717.	2.1	23

#	ARTICLE	IF	CITATIONS
21	VEGF inhibition: latest developments. Expert Review of Ophthalmology, 2007, 2, 621-632.	0.3	0
22	Therapeutic effects of ranibizumab in neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2007, 2, 679-693.	0.3	1
23	Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. British Journal of Ophthalmology, 2007, 91, 785-789.	2.1	30
24	Recurrence of choroidal neovascularisation after photodynamic therapy in patients with age-related macular degeneration. British Journal of Ophthalmology, 2007, 91, 753-756.	2.1	13
25	Photodynamic therapy in the anti-VEGF era. British Journal of Ophthalmology, 2007, 91, 707-708.	2.1	5
26	Current Treatment of Age-Related Macular Degeneration. Optometry and Vision Science, 2007, 84, E559-E572.	0.6	29
27	Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Exudative Age-Related Macular Degeneration and Diffuse Diabetic Macular Edema. Ophthalmic Research, 2007, 39, 139-142.	1.0	47
30	Complement, Innate Immunity and Ocular Disease. , 2007, 92, 105-114.		23
32	Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. British Journal of Ophthalmology, 2007, 91, 827-831.	2.1	48
33	Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. British Journal of Ophthalmology, 2007, 91, 1244-1246.	2.1	132
34	Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. British Journal of Ophthalmology, 2007, 91, 161-165.	2.1	135
35	The Therapeutic Effects of Intravitreal Bevacizumab in a Patient with Recalcitrant Idiopathic Polypoidal Choroidal Vasculopathy. Seminars in Ophthalmology, 2007, 22, 127-131.	0.8	28
36	Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2007, 125, 1357.	2.6	76
37	Anti-vascular Endothelial Growth Factor Bevacizumab (Avastin) for Radiation Retinopathy. JAMA Ophthalmology, 2007, 125, 751.	2.6	120
38	Vascular Endothelial Growth Factor in Aqueous Humor Before and After Intravitreal Injection of Bevacizumab in Eyes With Diabetic Retinopathy. JAMA Ophthalmology, 2007, 125, 1363.	2.6	80
39	INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR RETINAL ANGIOMATOUS PROLIFERATION. Retina, 2007, 27, 451-457.	1.0	82
40	INFLUENCE OF VERTEPORFIN PHOTODYNAMIC THERAPY ON INFLAMMATION IN HUMAN CHOROIDAL NEOVASCULAR MEMBRANES SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 713-723.	1.0	32
41	STANDARDIZED VISUAL ACUITY RESULTS ASSOCIATED WITH PRIMARY VERSUS SECONDARY BEVACIZUMAB (AVASTIN) TREATMENT FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 701-706.	1.0	39

#	ARTICLE	IF	CITATIONS
42	TREATMENT OF NAIVE LESIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIB. Retina, 2007, 27, 851-856.	1.0	23
43	Neovascular AMD: Out of the Forest and Into the Trees. Retina, 2007, 27, 655-661.	1.0	2
44	TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 133-140.	1.0	194
45	REBOUND MACULAR EDEMA FOLLOWING BEVACIZUMAB (AVASTIN) THERAPY FOR RETINAL VENOUS OCCLUSIVE DISEASE. Retina, 2007, 27, 426-431.	1.0	121
46	INTRAVITREAL BEVACIZUMAB (AVASTIN) IN CENTRAL RETINAL VEIN OCCLUSION. Retina, 2007, 27, 1013-1019.	1.0	64
47	INTRAVITREAL BEVACIZUMAB COMBINED WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF OCCULT CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH SEROUS PIGMENT EPITHELIUM DETACHMENT IN AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 891-896.	1.0	36
48	INTRAVITREAL BEVACIZUMAB INJECTIONS FOR TREATMENT OF CENTRAL RETINAL VEIN OCCLUSION. Retina, 2007, 27, 1004-1012.	1.0	113
49	RANIBIZUMAB FOR TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 846-850.	1.0	28
50	Avastin Versus Lucentis: Ethical Issues in Treatment of Age-Related Macular Degeneration. Retina, 2007, 27, 1163-1165.	1.0	15
51	Antiangiogenic Therapy in Neovascular Age-related Macular Degeneration. International Ophthalmology Clinics, 2007, 47, 117-137.	0.3	12
52	INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 439-444.	1.0	154
54	INTRAVITREAL BEVACIZUMAB FOR PREVIOUSLY TREATED CHOROIDAL NEOVASCULARIZATION FROM AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 432-438.	1.0	64
55	CHANGES OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN). Retina, 2007, 27, 1044-1047.	1.0	140
56	INTRAVITREAL BEVACIZUMAB FOR THE MANAGEMENT OF CHOROIDAL NEOVASCULARIZATION IN PSEUDOXANTHOMA ELASTICUM. Retina, 2007, 27, 897-902.	1.0	82
57	Ocular Neovascularization: Basic Mechanisms and Therapeutic Advances. Survey of Ophthalmology, 2007, 52, S3-S19.	1.7	118
58	Intravitreal Bevacizumab. Ophthalmology, 2007, 114, 400.	2.5	1
60	Relative Cost of a Line of Vision in Age-Related Macular Degeneration. Ophthalmology, 2007, 114, 847-854.	2.5	40
61	Interventions for Branch Retinal Vein Occlusion. Ophthalmology, 2007, 114, 835-854.	2.5	131

#	ARTICLE	IF	CITATIONS
62	Pharmacokinetics of Intravitreal Bevacizumab (Avastin). <i>Ophthalmology</i> , 2007, 114, 855-859.	2.5	636
63	Intravitreal Bevacizumab (Avastin) for Myopic Choroidal Neovascularization. <i>Ophthalmology</i> , 2007, 114, 2190-2196.e2.	2.5	127
64	Association of Complement Factor H and LOC387715 Genotypes with Response of Exudative Age-Related Macular Degeneration to Intravitreal Bevacizumab. <i>Ophthalmology</i> , 2007, 114, 2168-2173.	2.5	195
65	Pharmacokinetics of Intravitreal Ranibizumab (Lucentis). <i>Ophthalmology</i> , 2007, 114, 2179-2182.	2.5	497
66	Intravitreal Bevacizumab for Idiopathic Choroidal Neovascularization After Previous Injection With Posterior Subtenon Triamcinolone. <i>American Journal of Ophthalmology</i> , 2007, 143, 507-509.e1.	1.7	38
67	Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy, Secondary to Punctate Inner Choroidopathy, or of Idiopathic Origin. <i>American Journal of Ophthalmology</i> , 2007, 143, 977-983.e1.	1.7	159
68	Bevacizumab (Avastin) for Diabetic Macular Edema in Previously Vitrectomized Eyes. <i>American Journal of Ophthalmology</i> , 2007, 144, 124-126.	1.7	122
69	Peripheral Retinopathy and Maculopathy in High-dose Tamoxifen Therapy. <i>American Journal of Ophthalmology</i> , 2007, 144, 126-128.	1.7	99
70	Retinal Pigment Epithelium Tears After Intravitreal Bevacizumab in Pigment Epithelium Detachment. <i>American Journal of Ophthalmology</i> , 2007, 144, 294-296.	1.7	30
71	Treatment of Exudative Age-related Macular Degeneration: Many Factors to Consider. <i>American Journal of Ophthalmology</i> , 2007, 144, 281-283.	1.7	14
72	Anti-VEGF Agents in the Treatment of Neovascular Age-related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday Patients. <i>American Journal of Ophthalmology</i> , 2007, 144, 627-637.e2.	1.7	210
73	Intravitreal Bevacizumab Therapy for Neovascular Age-related Macular Degeneration with Large Submacular Hemorrhage. <i>American Journal of Ophthalmology</i> , 2007, 144, 886-892.e2.	1.7	91
74	VEGF modulation of retinal pigment epithelium resistance. <i>Experimental Eye Research</i> , 2007, 85, 762-771.	1.2	123
75	Regression of neovascular posterior capsule vessels by intravitreal bevacizumab. <i>Journal of Cataract and Refractive Surgery</i> , 2007, 33, 1113-1115.	0.7	17
76	Retinal and choroidal microangiopathies: Therapeutic opportunities. <i>Microvascular Research</i> , 2007, 74, 131-144.	1.1	60
77	Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. <i>Current Medical Research and Opinion</i> , 2007, 23, 477-487.	0.9	52
78	Combination Therapy for Choroidal Neovascularisation. <i>Drugs and Aging</i> , 2007, 24, 979-990.	1.3	18
79	Targeting Vascular Endothelial Growth Factor. <i>Drugs and Aging</i> , 2007, 24, 643-662.	1.3	43

#	ARTICLE	IF	CITATIONS
80	Bevacizumab for Neovascular Ocular Diseases. <i>Annals of Pharmacotherapy</i> , 2007, 41, 614-625.	0.9	156
81	Emerging Therapies for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. <i>BioDrugs</i> , 2007, 21, 245-257.	2.2	63
82	Pegaptanib sodium for the treatment of ocular vascular disease. <i>Expert Review of Ophthalmology</i> , 2007, 2, 45-60.	0.3	1
83	Intravitreal triamcinolone acetonide: potential complications. <i>Expert Review of Ophthalmology</i> , 2007, 2, 987-999.	0.3	2
84	Atlas of Fundus Autofluorescence Imaging. , 2007, , .		51
85	Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration. <i>Core Evidence</i> , 2007, .	4.7	5
86	Comparison of the original Amsler grid with the preferential hyperacuity perimeter for detecting choroidal neovascularization in age-related macular degeneration. <i>Arquivos Brasileiros De Oftalmologia</i> , 2007, 70, 771-6.	0.2	20
89	Error Correction and Quantitative Subanalysis of Optical Coherence Tomography Data Using Computer-Assisted Grading. , 2007, 48, 839.		114
90	Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. <i>British Journal of Ophthalmology</i> , 2007, 91, 128-130.	2.1	17
91	Intravitreal Bevacizumab Therapy for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: 6-Month Results of an Open-Label Uncontrolled Clinical Study. <i>European Journal of Ophthalmology</i> , 2007, 17, 230-237.	0.7	32
92	Managing neovascular age-related macular degeneration: a step into the light. <i>Medical Journal of Australia</i> , 2007, 186, 276-277.	0.8	1
93	Molecular targets for retinal vascular diseases. <i>Journal of Cellular Physiology</i> , 2007, 210, 575-581.	2.0	42
94	Age-related maculopathy in the light of ischaemia. <i>Australasian journal of optometry, The</i> , 2007, 90, 263-271.	0.6	17
95	Intravitreal VEGF-inhibitors: is Avastin® a generic substitute for Lucentis®?. <i>Acta Ophthalmologica</i> , 2007, 85, 2-4.	0.4	17
96	Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. <i>Acta Ophthalmologica</i> , 2007, 85, 563-565.	0.4	12
97	Treatment of choroidal neovascularization using intravitreal bevacizumab. <i>Acta Ophthalmologica</i> , 2007, 85, 526-533.	0.4	20
98	Guidance for the treatment of neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2007, 85, 486-494.	0.4	45
99	Bevacizumab (Avastin) for the treatment of neovascular glaucoma. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 494-496.	1.3	61

#	ARTICLE	IF	CITATIONS
100	Hughes syndrome. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 496-498.	1.3	3
101	New algorithm for assessing patient suitability for macular translocation surgery. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 448-457.	1.3	12
102	Management of neovascular age-related macular degeneration. <i>Progress in Retinal and Eye Research</i> , 2007, 26, 437-451.	7.3	79
103	Large subretinal hemorrhage after intravitreal bevacizumab (Avastin®) for age-related macular degeneration. <i>Annals of Ophthalmology</i> , 2007, 39, 51-52.	0.0	11
107	Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. <i>Documenta Ophthalmologica</i> , 2007, 114, 37-44.	1.0	45
109	Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 215-220.	1.0	34
110	Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1045-1048.	1.0	54
111	Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 941-948.	1.0	84
112	Surgical induction of choroidal neovascularization in a porcine model. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1189-1198.	1.0	24
113	RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1037-1040.	1.0	40
114	Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1273-1280.	1.0	57
115	Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 1597-1602.	1.0	57
116	Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 246, 17-25.	1.0	35
117	Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 246, 81-87.	1.0	401
120	Intravitreal anti-VEGF therapy in neovascular age-related macular degeneration: Bevacizumab versus Ranibizumab. <i>Spektrum Der Augenheilkunde</i> , 2008, 22, 370-375.	0.2	1
121	Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. <i>Japanese Journal of Ophthalmology</i> , 2008, 52, 52-56.	0.9	21
122	Intraocular inflammation following intravitreal injection of bevacizumab. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2008, 246, 779-781.	1.0	89
123	A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (Case reports). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2008, 246, 1235-1239.	1.0	82

#	ARTICLE	IF	CITATIONS
124	A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. <i>Trials</i> , 2008, 9, 56.	0.7	31
125	Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib <sup>®</sup> treatment. <i>Acta Ophthalmologica</i> , 2008, 86, 456-458.	0.6	33
126	Complications in patients after intravitreal injection of bevacizumab. <i>Acta Ophthalmologica</i> , 2008, 86, 372-376.	0.6	179
127	A prospective study on intravitreal bevacizumab (Avastin <sup>®</sup> ) for neovascular age-related macular degeneration of different durations. <i>Acta Ophthalmologica</i> , 2008, 86, 482-489.	0.6	86
128	Combined treatment of acute subretinal haemorrhages with intravitreal recombinant tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. <i>Acta Ophthalmologica</i> , 2008, 86, 490-494.	0.6	91
129	Natural history of choroidal neovascularization after surgical induction in an animal model. <i>Acta Ophthalmologica</i> , 2008, 86, 495-503.	0.6	21
130	The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. <i>Eye</i> , 2008, 22, 761-767.	1.1	40
131	Anti-VEGF therapy: comparison of current and future agents. <i>Eye</i> , 2008, 22, 1330-1336.	1.1	92
132	Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. <i>Eye</i> , 2008, 22, 82-86.	1.1	67
133	Progress in understanding and treating age-related macular degeneration. <i>Eye</i> , 2008, 22, 739-741.	1.1	4
134	Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. <i>Australasian journal of optometry</i> , The, 2008, 91, 427-437.	0.6	60
135	Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. <i>Clinical and Experimental Ophthalmology</i> , 2008, 36, 748-755.	1.3	27
136	Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. <i>FEBS Letters</i> , 2008, 582, 3097-3102.	1.3	61
138	Clinical and Histological Aspects of CNV Formation: Studies in an Animal Model. <i>Acta Ophthalmologica</i> , 2008, 86, 1-28.	0.6	27
139	Neovascular Age-Related Macular Degeneration. <i>Drugs</i> , 2008, 68, 1029-1036.	4.9	155
140	Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. , 2008, , CD005139.		60
141	Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: A One-year Prospective Study. <i>American Journal of Ophthalmology</i> , 2008, 145, 249-256.e2.	1.7	188
142	Treatment of Neovascular Age-related Macular Degeneration with Intravitreal Bevacizumab: Efficacy of Three Consecutive Monthly Injections. <i>American Journal of Ophthalmology</i> , 2008, 146, 91-95.	1.7	37



#	ARTICLE	IF	CITATIONS
143	Effect of Bevacizumab on Human Corneal Endothelial Cells: A Six-month Follow-up Study. American Journal of Ophthalmology, 2008, 146, 688-691.e2.	1.7	35
144	Combined Intravitreal Bevacizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation. American Journal of Ophthalmology, 2008, 146, 935-941.e1.	1.7	44
145	Age-related Macular Degeneration: An Update on Treatment. American Journal of Medicine, 2008, 121, 279-281.	0.6	9
146	Quantitative Comparison of Optical Coherence Tomography after Pegaptanib or Bevacizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 347-354.e2.	2.5	40
147	The Effect of Topical Bevacizumab on Corneal Neovascularization. Ophthalmology, 2008, 115, e33-e38.	2.5	200
148	Acute Intraocular Inflammation after Intravitreal Injections of Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration. Ophthalmology, 2008, 115, 1911-1915.e1.	2.5	108
149	Anti-vascular Endothelial Growth Factor Pharmacotherapy for Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 1837-1846.	2.5	132
150	Relationship Between Optical Coherence Tomography Retinal Parameters and Visual Acuity in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 2206-2214.	2.5	94
151	Shall we use Avastin <sup>®</sup> or Lucentis <sup>®</sup> for ocular neovascularization?. Acta Ophthalmologica, 2008, 86, 352-355.	0.6	6
154	Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia. Canadian Journal of Ophthalmology, 2008, 43, 576-580.	0.4	17
155	Pharmacotherapy of age-related macular degeneration. Expert Opinion on Pharmacotherapy, 2008, 9, 3045-3052.	0.9	10
156	Toxicity and Intraocular Properties of a Novel Long-Acting Anti-Proliferative and Anti-Angiogenic Compound IMS2186. Current Eye Research, 2008, 33, 599-609.	0.7	17
157	Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. British Journal of Ophthalmology, 2008, 92, 213-216.	2.1	364
159	Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2008, 92, 70-73.	2.1	232
160	Treatment of peripapillary choroidal neovascular membranes with intravitreal bevacizumab. British Journal of Ophthalmology, 2008, 92, 1244-1247.	2.1	20
161	Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2008, 92, 661-666.	2.1	148
162	Emerging Roles for the CD36 Scavenger Receptor as a Potential Therapeutic Target for Corneal Neovascularization. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2008, 8, 255-272.	0.6	8
163	Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion. British Journal of Ophthalmology, 2008, 92, 1424-1428.	2.1	17

#	ARTICLE	IF	CITATIONS
164	Management of choroidal vascularisation. British Journal of Ophthalmology, 2008, 92, 445-446.	2.1	2
165	Bevacizumab Treatment for Subfoveal Choroidal Neovascularization From Causes Other Than Age-Related Macular Degeneration. JAMA Ophthalmology, 2008, 126, 941.	2.6	73
166	Ranibizumab for neovascular age-related macular degeneration. American Journal of Health-System Pharmacy, 2008, 65, 1805-1814.	0.5	25
167	Age-related macular degeneration: diagnosis and management. British Medical Bulletin, 2008, 85, 127-149.	2.7	93
168	Effects of Bevacizumab (Avastin) on Retinal Cells in Organotypic Culture. , 2008, 49, 3164.		38
169	A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. British Journal of Ophthalmology, 2008, 92, 1636-1641.	2.1	54
170	Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. British Journal of Ophthalmology, 2008, 92, 518-522.	2.1	171
176	Intravitreal Bevacizumab and Triamcinolone Acetonide Combination Therapy for Exudative Neovascular Age-Related Macular Degeneration: Short-Term Optical Coherence Tomography Results. Journal of Ocular Pharmacology and Therapeutics, 2008, 24, 15-24.	0.6	16
178	Effect of Bevacizumab on Inflammation and Proliferation in Human Choroidal Neovascularization. JAMA Ophthalmology, 2008, 126, 782.	2.6	42
179	Correspondence. Retina, 2008, 28, 1023.	1.0	1
181	COMPARISON OF 2.5 mg/kg AND 5 mg/kg SYSTEMIC BEVACIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2008, 28, 1375-1386.	1.0	10
182	Intravitreal Bevacizumab in the Management of Choroidal Neovascular Membrane Secondary to Choroidal Osteoma. European Journal of Ophthalmology, 2008, 18, 466-468.	0.7	22
183	INTRAVITREAL BEVACIZUMAB (AVASTIN) AS A TREATMENT FOR REFRACTORY MACULAR EDEMA IN PATIENTS WITH UVEITIS. Retina, 2008, 28, 41-45.	1.0	106
184	INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF RETINAL ANGIOMATOUS PROLIFERATION. Retina, 2008, 28, 689-695.	1.0	43
185	REPEATED INTRAVITREAL INJECTION OF BEVACIZUMAB FOR CLINICALLY SIGNIFICANT DIABETIC MACULAR EDEMA. Retina, 2008, 28, 1314-1318.	1.0	28
186	INCIDENCE OF ACUTE ONSET ENDOPHTHALMITIS FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTION. Retina, 2008, 28, 564-567.	1.0	145
187	CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIA. Retina, 2008, 28, 1308-1313.	1.0	77
188	Effect of Intracameral Bevacizumab Injection on Corneal Endothelium in Rabbits. Cornea, 2008, 27, 1151-1155.	0.9	22

#	ARTICLE	IF	CITATIONS
189	Correspondence. Retina, 2008, 28, 1023-1024.	1.0	0
191	OUTCOME OF BEVACIZUMAB (AVASTIN) INJECTION IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION AND LOW VISUAL ACUITY. Retina, 2008, 28, 1302-1307.	1.0	25
192	INTRAVITREAL BEVACIZUMAB (AVASTIN) PREVENTION OF PANRETINAL PHOTOCOAGULATION-INDUCED COMPLICATIONS IN PATIENTS WITH SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. Retina, 2008, 28, 1319-1324.	1.0	45
193	Effects of Macular Ischemia on the Outcome of Intravitreal Bevacizumab Therapy for Diabetic Macular Edema. Retina, 2008, 28, 957-963.	1.0	108
194	Correspondence. Retina, 2008, 28, 1024-1025.	1.0	0
195	PRIMARY INTRAVITREAL BEVACIZUMAB FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2008, 28, 1387-1394.	1.0	56
196	SHORT-TERM INTRAOCULAR PRESSURE TRENDS AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN). Retinal Cases and Brief Reports, 2008, 2, 234-235.	0.3	4
197	Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany. Clinical Ophthalmology, 2008, 2, 253.	0.9	10
198	Treatment of age-related macular degeneration: focus on ranibizumab. Clinical Ophthalmology, 2008, 2, 1.	0.9	40
199	Current and emerging therapies for the treatment of age-related macular degeneration. Clinical Ophthalmology, 2008, 2, 377.	0.9	46
200	Long-term Effect of Intravitreal Bevacizumab for CNV Secondary to Age-Related Macular Degeneration. Journal of Korean Ophthalmological Society, 2008, 49, 1935.	0.0	9
201	Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration. Clinical Ophthalmology, 2008, 2, 727.	0.9	9
202	The Therapeutic Effects of Bevacizumab in Patients with Polypoidal Choroidal Vasculopathy. Korean Journal of Ophthalmology: KJO, 2008, 22, 92.	0.5	63
203	Treatment of neovascular age-related macular degeneration: Current therapies. Clinical Ophthalmology, 2009, 3, 175.	0.9	28
204	Short-term Safety and Efficacy of Intravitreal Bavacizumab Injection. Journal of Korean Ophthalmological Society, 2009, 50, 219.	0.0	4
205	Age-related macular degeneration: current treatments. Clinical Ophthalmology, 2009, 3, 155.	0.9	43
206	Short-term Efficacy of Intravitreal Bavacizumab for Polypoidal Choroidal Vasculopathy. Journal of Korean Ophthalmological Society, 2009, 50, 51.	0.0	4
207	Effects and Prognostic Factors of Intravitreal Bevacizumab Injection on Choroidal Neovascularization from Age-Related Macular Degeneration. Journal of Korean Ophthalmological Society, 2009, 50, 202.	0.0	7

#	ARTICLE	IF	CITATIONS
208	Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin®) for AMD followed by contralateral sympathetic ophthalmia. <i>Clinical Ophthalmology</i> , 2009, 3, 457.	0.9	35
209	Exudative Age-Related Macular Degeneration: Current Therapies and Potential Treatments. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2225.	0.1	0
210	Evaluation of Optical Coherence Tomography Retinal Thickness Parameters for Use in Clinical Trials for Neovascular Age-Related Macular Degeneration. , 2009, 50, 3378.		58
211	Choroidal Neovascularization in Angioid Streaks and Pseudoxanthoma Elasticum: 1 Year Follow-Up. <i>European Journal of Ophthalmology</i> , 2009, 19, 151-153.	0.7	20
212	Anti-Vascular Endothelial Growth Factor Activity in the Bevacizumab and Triamcinolone Acetonide Combination for Intravitreal Use. <i>European Journal of Ophthalmology</i> , 2009, 19, 842-847.	0.7	3
213	Pharmacotherapy of Retinal Diseases with Ranibizumab. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2371.	0.1	1
214	Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. <i>British Journal of Ophthalmology</i> , 2009, 93, 150-154.	2.1	93
215	Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation. <i>British Journal of Ophthalmology</i> , 2009, 93, 159-165.	2.1	7
216	Simultaneous Intravitreal and Intracameral Injection of Bevacizumab (Avastin) in Neovascular Glaucoma. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 259-264.	0.6	12
217	Pigment Epithelium-derived Factor Maintains Retinal Pigment Epithelium Function by Inhibiting Vascular Endothelial Growth Factor-R2 Signaling through $\beta$ -Secretase. <i>Journal of Biological Chemistry</i> , 2009, 284, 30177-30186.	1.6	62
218	Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. <i>British Journal of Ophthalmology</i> , 2009, 93, 1027-1032.	2.1	32
219	Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration: an optical coherence tomography study. <i>British Journal of Ophthalmology</i> , 2009, 93, 1353-1358.	2.1	29
220	Intravitreal Bevacizumab versus Triamcinolone Acetonide for Exudative Age-Related Macular Degeneration. <i>Ophthalmic Research</i> , 2009, 41, 21-27.	1.0	20
221	Short-Term Safety and Efficacy of a Single Intravitreal Bevacizumab Injection for the Management of Polypoidal Choroidal Vasculopathy. <i>Ophthalmologica</i> , 2009, 223, 85-92.	1.0	45
224	Intravitreal Bevacizumab (Avastin) for the Treatment of Cystoid Macular Edema in Behçet Disease. <i>Ocular Immunology and Inflammation</i> , 2009, 17, 59-64.	1.0	32
225	Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2009, 223, 370-375.	1.0	60
226	Age-related macular degeneration. <i>Journal of the Royal Society of Medicine</i> , 2009, 102, 56-61.	1.1	32
227	Age-related maculopathy – Linking aetiology and pathophysiological changes to the ischaemia hypothesis. <i>Progress in Retinal and Eye Research</i> , 2009, 28, 63-86.	7.3	116

#	ARTICLE	IF	CITATIONS
228	Effects of intravitreal bevacizumab (Avastin®) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration. <i>Journal of Clinical Ultrasound</i> , 2010, 38, 66-70.	0.4	20
229	A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 1-11.	1.0	96
230	Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2009, 247, 735-743.	1.0	83
231	Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the pan-american collaborative retina study group (PACORES) at the 12-month follow-up. <i>Japanese Journal of Ophthalmology</i> , 2009, 53, 125-130.	0.9	9
232	Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. <i>International Ophthalmology</i> , 2009, 29, 349-357.	0.6	24
233	Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections. <i>Documenta Ophthalmologica</i> , 2009, 118, 81-88.	1.0	18
234	Pattern electroretinographic results after photodynamic therapy alone and photodynamic therapy in combination with intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. <i>Documenta Ophthalmologica</i> , 2009, 119, 37-42.	1.0	4
236	Bevacizumab: a new hope?. <i>Eye</i> , 2009, 23, 1755-1757.	1.1	0
237	Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. <i>Eye</i> , 2009, 23, 694-702.	1.1	47
238	Early response of retinal angiomatous proliferation treated with intravitreal pegaptanib: a retrospective review. <i>Eye</i> , 2009, 23, 530-535.	1.1	10
239	Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration. <i>Eye</i> , 2009, 23, 453-460.	1.1	19
240	What's fueling the biotech engine? 2008. <i>Nature Biotechnology</i> , 2009, 27, 987-993.	9.4	58
241	Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. <i>Experimental Eye Research</i> , 2009, 88, 522-527.	1.2	57
242	Cardiovascular Risk and Antiangiogenic Therapy for Age-related Macular Degeneration. <i>Survey of Ophthalmology</i> , 2009, 54, 339-348.	1.7	47
243	Bevacizumab (Avastin) for the Treatment of Ocular Disease. <i>Survey of Ophthalmology</i> , 2009, 54, 372-400.	1.7	125
244	Applying the CONSORT and STROBE Statements to Evaluate the Reporting Quality of Neovascular Age-related Macular Degeneration Studies. <i>Ophthalmology</i> , 2009, 116, 286-296.e4.	2.5	70
245	Economic Implications of Current Age-Related Macular Degeneration Treatments. <i>Ophthalmology</i> , 2009, 116, 481-487.	2.5	27
246	Verteporfin Photodynamic Therapy Combined With Intravitreal Bevacizumab for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2009, 116, 747-755.e1.	2.5	83

#	ARTICLE	IF	CITATIONS
247	Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. <i>Ophthalmology</i> , 2009, 116, 1488-1497.e1.	2.5	125
248	Association of Retinal Sensitivity and Morphology during Antiangiogenic Treatment of Retinal Vein Occlusion over One Year. <i>Ophthalmology</i> , 2009, 116, 2415-2421.	2.5	47
249	Effects of Intraocular Ranibizumab and Bevacizumab in Transgenic Mice Expressing Human Vascular Endothelial Growth Factor. <i>Ophthalmology</i> , 2009, 116, 1748-1754.	2.5	36
250	Intravitreal Bevacizumab Treatment for Choroidal Neovascularization in Pathologic Myopia: 12-month Results. <i>American Journal of Ophthalmology</i> , 2009, 147, 84-93.e1.	1.7	111
251	Central Retinal Sensitivity After Intravitreal Injection of Bevacizumab for Myopic Choroidal Neovascularization. <i>American Journal of Ophthalmology</i> , 2009, 147, 816-824.e1.	1.7	40
252	Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a Prospective Study. <i>American Journal of Ophthalmology</i> , 2009, 148, 59-65.e1.	1.7	71
253	Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapies. <i>American Journal of Ophthalmology</i> , 2009, 148, 647-656.	1.7	100
254	Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial. <i>American Journal of Ophthalmology</i> , 2009, 148, 875-882.e1.	1.7	66
255	Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration. <i>Drugs and Aging</i> , 2009, 26, 295-320.	1.3	27
256	Photoreceptor status after antivasular endothelial growth factor therapy in exudative age-related macular degeneration. <i>British Journal of Ophthalmology</i> , 2009, 93, 622-626.	2.1	58
257	Retinal Angiography and Optical Coherence Tomography. , 2009, , .		18
258	Evaluation of Differential Toxicity of Varying Doses of Bevacizumab on Retinal Ganglion Cells, Retinal Pigment Epithelial Cells, and Vascular Endothelial Growth Factor-Enriched Choroidal Endothelial Cells. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 507-512.	0.6	25
259	Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2009, 87, 404-407.	0.6	25
260	Efficacy of intravitreal bevacizumab (Avastin®) therapy for early and advanced neovascular age-related macular degeneration. <i>Acta Ophthalmologica</i> , 2009, 87, 611-617.	0.6	24
261	Intravitreal bevacizumab (Avastin®) for neovascular age-related macular degeneration in treatment-naïve patients. <i>Acta Ophthalmologica</i> , 2009, 87, 714-719.	0.6	24
262	Clinical and histological findings after intravitreal injection of bevacizumab (Avastin®) in a porcine model of choroidal neovascularization. <i>Acta Ophthalmologica</i> , 2010, 88, 300-308.	0.6	14
263	Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). <i>British Journal of Ophthalmology</i> , 2009, 93, 457-462.	2.1	111
264	BEVACIZUMAB (AVASTIN) AND RANIBIZUMAB (LUCENTIS) FOR CHOROIDAL NEOVASCULARIZATION IN MULTIFOCAL CHOROIDITIS. <i>Retina</i> , 2009, 29, 8-12.	1.0	91



#	ARTICLE	IF	CITATIONS
265	EFFECT OF RANIBIZUMAB RETREATMENT FREQUENCY ON NEUROSENSORY RETINAL VOLUME IN NEOVASCULAR AMD. <i>Retina</i> , 2009, 29, 592-600.	1.0	13
266	BEVACIZUMAB IN MACULAR EDEMA. <i>Retina</i> , 2009, 29, 941-948.	1.0	4
267	INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS. <i>Retina</i> , 2009, 29, 875-912.	1.0	215
268	STRATEGIES FOR INHIBITING VASCULAR ENDOTHELIAL GROWTH FACTOR. <i>Retina</i> , 2009, 29, S15-S17.	1.0	3
269	COMPARISON OF INTRAVITREAL BEVACIZUMAB FOLLOWED BY RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 1067-1073.	1.0	45
270	SHORT-TERM EFFECTIVENESS OF INTRAVITREAL BEVACIZUMAB VERSUS RANIBIZUMAB INJECTIONS FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 1235-1241.	1.0	24
271	VASCULAR EVENTS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAOCULAR BEVACIZUMAB. <i>Retina</i> , 2009, 29, 1404-1408.	1.0	12
272	INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF CHOROIDDAL NEOVASCULARIZATION FROM A TRAUMATIC CHOROIDDAL RUPTURE IN A 9-YEAR-OLD CHILD. <i>Retinal Cases and Brief Reports</i> , 2009, 3, 125-127.	0.3	11
273	Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 158-165.	1.3	110
274	INTRAVITREAL BEVACIZUMAB FOR TREATMENT-NAÏVE PATIENTS WITH SUBFOVEAL OCCULT CHOROIDDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 1227-1234.	1.0	14
275	INTRAVITREAL RANIBIZUMAB FOR THE PRIMARY TREATMENT OF CHOROIDDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA. <i>Retina</i> , 2009, 29, 750-756.	1.0	91
276	EFFICACY OF 1.25 MG VERSUS 2.5 MG INTRAVITREAL BEVACIZUMAB FOR DIABETIC MACULAR EDEMA. <i>Retina</i> , 2009, 29, 292-299.	1.0	81
277	INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT FOR RETINAL ANGIOMATOUS PROLIFERATION. <i>Retina</i> , 2009, 29, 740-749.	1.0	30
278	INTRAVITREAL INJECTION OF 2.5 mg VERSUS 1.25 mg BEVACIZUMAB (AVASTIN) FOR TREATMENT OF CNV ASSOCIATED WITH AMD. <i>Retina</i> , 2009, 29, 319-324.	1.0	49
279	SAFETY OF REPEAT INTRAVITREAL INJECTIONS OF BEVACIZUMAB VERSUS RANIBIZUMAB. <i>Retina</i> , 2009, 29, 313-318.	1.0	114
280	EFFECTS OF INTRAVITREAL BEVACIZUMAB IN REPEATED DOSES. <i>Retina</i> , 2009, 29, 1346-1355.	1.0	12
281	Suppression and Regression of Choroidal Neovascularization by the Multitargeted Kinase Inhibitor Pazopanib. <i>JAMA Ophthalmology</i> , 2009, 127, 494.	2.6	76
282	Intravitreal Injection of Bevacizumab before Vitrectomy for Proliferative Diabetic Retinopathy. <i>European Journal of Ophthalmology</i> , 2009, 19, 848-852.	0.7	77

#	ARTICLE	IF	CITATIONS
283	VISUAL OUTCOMES AND GROWTH FACTOR CHANGES OF TWO DOSAGES OF INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2009, 29, 1218-1226.	1.0	24
285	AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF PEGAPTANIB OR RANIBIZUMAB IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2010, 30, 1034-1038.	1.0	22
286	EXPERIMENTAL MODEL OF INTRAVITREAL INJECTION TECHNIQUES. <i>Retina</i> , 2010, 30, 167-173.	1.0	40
287	RESULTS OF 1-YEAR FOLLOW-UP EXAMINATIONS AFTER INTRAVITREAL BEVACIZUMAB ADMINISTRATION FOR IDIOPATHIC CHOROIDAL NEOVASCULARIZATION. <i>Retina</i> , 2010, 30, 733-738.	1.0	26
288	STERILE ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB OBTAINED FROM A SINGLE BATCH. <i>Retina</i> , 2010, 30, 485-490.	1.0	58
289	INTRAVITREAL BEVACIZUMAB IN VASCULAR PIGMENT EPITHELIUM DETACHMENT AS A RESULT OF SUBFOVEAL OCCULT CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2010, 30, 1420-1425.	1.0	29
290	EFFECT OF PHOTODYNAMIC THERAPY ALONE OR COMBINED WITH POSTERIOR SUBTENON TRIAMCINOLONE ACETONIDE OR INTRAVITREAL BEVACIZUMAB ON CHOROIDAL HYPOFLUORESCENCE BY INDOCYANINE GREEN ANGIOGRAPHY. <i>Retina</i> , 2010, 30, 495-502.	1.0	17
291	INTRAVITREAL BEVACIZUMAB INJECTION FOR CENTRAL SEROUS CHORIORETINOPATHY. <i>Retina</i> , 2010, 30, 100-106.	1.0	121
292	POSITIVE RESPONSE TO INTRAVITREAL RANIBIZUMAB IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PUNCTATE INNER CHOROIDOPATHY. <i>Retina</i> , 2010, 30, 1400-1404.	1.0	28
293	LONG-TERM OUTCOMES OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR THE MANAGEMENT OF CHOROIDAL NEOVASCULARIZATION IN PSEUDOXANTHOMA ELASTICUM. <i>Retina</i> , 2010, 30, 748-755.	1.0	61
294	INTRAVITREAL BEVACIZUMAB DURING PREGNANCY. <i>Retina</i> , 2010, 30, 1405-1411.	1.0	83
295	INTRAVITREAL BEVACIZUMAB ALONE VERSUS COMBINED VERTEPORFIN PHOTODYNAMIC THERAPY AND INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2010, 30, 548-554.	1.0	17
297	Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration. <i>Ophthalmology and Eye Diseases</i> , 2010, 2, OED.S4878.	1.2	93
300	Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 467-476.	1.0	29
301	Surgery for CNV and autologous choroidal RPE patch transplantation: exposing the submacular space. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 37-47.	1.0	46
302	Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 543-550.	1.0	38
303	Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 785-791.	1.0	96
304	Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients. <i>Japanese Journal of Ophthalmology</i> , 2010, 54, 124-128.	0.9	7



#	ARTICLE	IF	CITATIONS
305	Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Japanese Journal of Ophthalmology, 2010, 54, 571-577.	0.9	29
306	Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration. International Ophthalmology, 2010, 30, 261-266.	0.6	18
307	Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population. Clinical and Experimental Ophthalmology, 2010, 38, 659-663.	1.3	9
309	Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. Eye, 2010, 24, 203-213.	1.1	23
310	Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye, 2010, 24, 816-824.	1.1	38
311	Effect of intravitreal ranibizumab in avascular pigment epithelial detachment. Eye, 2010, 24, 962-968.	1.1	35
312	Anti-VEGF therapy for choroidal neovascularisation previously treated with photodynamic therapy. Eye, 2010, 24, 1018-1023.	1.1	5
313	Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye, 2010, 24, 1708-1715.	1.1	71
314	Patients' knowledge and perspectives on wet age-related macular degeneration and its treatment. Clinical Ophthalmology, 2010, 4, 375.	0.9	13
315	Intravitreal Bevacizumab With or Without Photodynamic Therapy for the Treatment of Polypoidal Choroidal Vasculopathy. Journal of Korean Ophthalmological Society, 2010, 51, 684.	0.0	2
316	The Effect of Subconjunctival Injection of Bevacizumab After Resection of Muscle in Rabbit Models. Journal of Korean Ophthalmological Society, 2010, 51, 423.	0.0	2
317	Long-Term Tolerability and Serum Concentration of Bevacizumab (Avastin) when Injected in Newborn Rabbit Eyes. , 2010, 51, 3701.		34
318	The macular threshold protocol of the Humphrey visual field analyzer: a superior functional outcome of intravitreal bevacizumab for the treatment of neovascular age-related macular degeneration. Arquivos Brasileiros De Oftalmologia, 2010, 73, 111-115.	0.2	2
319	Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration. Clinical Ophthalmology, 2010, 4, 703.	0.9	21
320	The Effect of Intravitreal Bevacizumab in Patients with Acute Central Serous Chorioretinopathy. Korean Journal of Ophthalmology: KJO, 2010, 24, 155.	0.5	61
321	Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?. Clinical Ophthalmology, 2010, 4, 307.	0.9	8
322	Comparative Review of Ranibizumab versus Bevacizumab in the Treatment of Neovascular Age-related Macular Degeneration. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S2226.	0.4	0
323	Effects of Retinal Morphology on Contrast Sensitivity and Reading Ability in Neovascular Age-Related Macular Degeneration. , 2010, 51, 5431.		50

#	ARTICLE	IF	CITATIONS
324	Impact of Scanning Density on Measurements from Spectral Domain Optical Coherence Tomography. , 2010, 51, 1071.		56
325	Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration. British Journal of Ophthalmology, 2010, 94, 185-189.	2.1	47
326	MACULOPATHY DIAGNOSED WITH HIGH-RESOLUTION FOURIER-DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN EYES WITH PREVIOUSLY UNEXPLAINED VISUAL LOSS. Retinal Cases and Brief Reports, 2010, 4, 233-239.	0.3	1
327	A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. British Journal of Ophthalmology, 2010, 94, 174-179.	2.1	29
328	Bevacizumab vs Photodynamic Therapy for Choroidal Neovascularization in Multifocal Choroiditis. JAMA Ophthalmology, 2010, 128, 1100.	2.6	38
329	Update on combination therapy in wet age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 681-688.	0.3	1
330	Intravitreal Bevacizumab in Treatment of Idiopathic Persistent Central Serous Chorioretinopathy: A Prospective, Controlled Clinical Study. Current Eye Research, 2010, 35, 91-98.	0.7	88
331	Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema: Early Results. Trk Oftalmoloji Dergisi, 2010, 40, 145-150.	0.4	0
332	Neovascular age-related macular degeneration. , 2010, , 128-132.		3
333	Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: Short-term results. Indian Journal of Ophthalmology, 2010, 58, 291.	0.5	24
334	Antivascular Endothelial Growth Factors in Age-Related Macular Degeneration. Developments in Ophthalmology, 2010, 46, 21-38.	0.1	15
335	Combined Intravitreal Pharmacosurgery in Patients with Occult Choroidal Neovascularization Secondary to Wet Age-Related Macular Degeneration. Ophthalmologica, 2010, 224, 72-78.	1.0	12
336	Treatment of Choroidal Neovascularization in High Myopia. Current Drug Targets, 2010, 11, 630-644.	1.0	21
337	Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ: British Medical Journal, 2010, 340, c2459-c2459.	2.4	186
338	Effect of Brimonidine/Timolol Fixed Combination on Preventing the Short-Term Intraocular Pressure Increase after Intravitreal Injection of Ranibizumab. Klinische Monatsblatter Fur Augenheilkunde, 2010, 227, 280-284.	0.3	42
339	Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration. JAMA Ophthalmology, 2010, 128, 1273.	2.6	181
340	Inflammatory Mediators and Angiogenic Factors in Choroidal Neovascularization: Pathogenetic Interactions and Therapeutic Implications. Mediators of Inflammation, 2010, 2010, 1-14.	1.4	170
341	Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy,) Tj ETQq1 1 0.784314 rgBT /Ove 45, 36-40.	0.4	24

#	ARTICLE	IF	CITATIONS
342	Retinal Imaging and Image Analysis. IEEE Reviews in Biomedical Engineering, 2010, 3, 169-208.	13.1	1,021
343	Development of novel drugs for ocular diseases: possibilities for individualized therapy. Personalized Medicine, 2010, 7, 371-386.	0.8	5
344	Immediate changes in intraocular pressure after an intravitreal injection of 2.5mg of bevacizumab. Archivos De La Sociedad Espanola De Oftalmologia, 2010, 85, 364-369.	0.1	4
345	Current treatment options for retinal angiomatous proliferans (RAP). British Journal of Ophthalmology, 2010, 94, 672-677.	2.1	29
346	Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. British Journal of Ophthalmology, 2010, 94, 701-705.	2.1	41
348	Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration at Twenty-four Months: The Pan-American Collaborative Retina Study. Ophthalmology, 2010, 117, 1974-1981.e1.	2.5	34
349	A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2010, 117, 2134-2140.	2.5	264
350	Intravitreal bevacizumab for posterior capsule neovascularization. Saudi Journal of Ophthalmology, 2010, 24, 63-65.	0.3	1
351	Comparison of Intravitreal Triamcinolone Acetonide With Photodynamic Therapy and Intravitreal Bevacizumab with Photodynamic Therapy for Retinal Angiomatous Proliferation. American Journal of Ophthalmology, 2010, 149, 472-481.e1.	1.7	29
352	Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumabâ€”A Randomized Controlled Trial. American Journal of Ophthalmology, 2010, 149, 458-464.e1.	1.7	102
353	Combined Photodynamic Therapy With Verteporfin and Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy. American Journal of Ophthalmology, 2010, 149, 947-954.e1.	1.7	65
354	Combined intravitreal bevacizumab and triamcinolone in exudative ageâ€”related macular degeneration. Acta Ophthalmologica, 2010, 88, 630-634.	0.6	16
355	Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization. Acta Ophthalmologica, 2010, 88, e305-10.	0.6	9
356	Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary. Canadian Journal of Ophthalmology, 2010, 45, 501-508.	0.4	8
357	Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database. Canadian Journal of Ophthalmology, 2010, 45, 231-238.	0.4	30
358	Intraocular Properties of a Repository Urokinase Receptor Antagonist Å…36 Peptide in Rabbits. Current Eye Research, 2010, 35, 742-750.	0.7	1
359	Bevacizumab versus ranibizumab for the treatment of neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 603-615.	0.3	1
360	Comparing Treatment of Neovascular Age-related Macular Degeneration with Sequential Intravitreal Avastin and Macugen Versus Intravitreal Mono-therapyâ€”A Pilot Study. Current Eye Research, 2011, 36, 958-963.	0.7	8

#	ARTICLE	IF	CITATIONS
361	Radiation therapy in the treatment of exudative age-related macular degeneration. Expert Review of Ophthalmology, 2011, 6, 323-337.	0.3	1
362	Die altersabhÄngige Makuladegeneration â€” eine Åœbersicht. Zentralblatt Fur Arbeitsmedizin, Arbeitsschutz Und Ergonomie, 2011, 61, 270-286.	0.1	1
363	Bilateral Intravitreal Bevacizumab Injection for Exudative Age-Related Macular Degeneration: Effect of Baseline Visual Acuity. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 401-405.	0.6	5
364	Neovascular Age-Related Macular Degeneration. BioDrugs, 2011, 25, 171-189.	2.2	2
365	Intravitreal Bevacizumab for Exudative Age-Related Macular Degeneration in Clinical Practice. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 467-470.	0.6	8
367	Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab. Ophthalmologica, 2011, 225, 211-221.	1.0	51
368	Management of Neovascular AMD. , 2011, , 79-98.		0
369	Bevacizumab and Neovascular Age Related Macular Degeneration: Pathogenesis and Treatment. Seminars in Ophthalmology, 2011, 26, 69-76.	0.8	23
370	Drug Product Development for the Back of the Eye. AAPS Advances in the Pharmaceutical Sciences Series, 2011, , .	0.2	13
371	Pharmacotherapy for Neovascular Age-Related Macular Degeneration: An Analysis of the 100% 2008 Medicare Fee-For-Service Part B Claims File. American Journal of Ophthalmology, 2011, 151, 887-895.e1.	1.7	122
372	How the Comparison of Age-related Macular Degeneration Treatments Trial Results Will Impact Clinical Care. American Journal of Ophthalmology, 2011, 152, 509-514.	1.7	18
373	Effect of bevacizumab on postoperative adhesion formation in a rat uterine horn adhesion model and the correlation with vascular endothelial growth factor and Ki-67 immunopositivity. Fertility and Sterility, 2011, 95, 2638-2641.	0.5	27
374	Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease. Survey of Ophthalmology, 2011, 56, 95-113.	1.7	257
375	Effects and Complications of Bevacizumab Use in Patients with Retinopathy of Prematurity: A Multicenter Study in Taiwan. Ophthalmology, 2011, 118, 176-183.	2.5	141
376	Predicting visual outcomes for macular disease using optical coherence tomography. Saudi Journal of Ophthalmology, 2011, 25, 145-158.	0.3	29
377	Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Acta Ophthalmologica, 2011, 89, 647-653.	0.6	20
378	Ranibizumab treatment in patients with neovascular age-related macular degeneration and very low vision. Acta Ophthalmologica, 2011, 89, e97-e97.	0.6	5
380	Management of Neovascular Age-Related Macular Degeneration in Clinical Practice: Initiation, Maintenance, and Discontinuation of Therapy. Journal of Ophthalmology, 2011, 2011, 1-10.	0.6	5

#	ARTICLE	IF	CITATIONS
381	Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Korean Journal of Ophthalmology: KJO, 2011, 25, 231.	0.5	8
382	POSTERIOR VITREOUS DETACHMENT WITH MICROPLASMIN ALTERS THE RETINAL PENETRATION OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN RABBIT EYES. Retina, 2011, 31, 393-400.	1.0	22
383	SUSTAINED ELEVATED INTRAOCULAR PRESSURES AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, RANIBIZUMAB, AND PEGAPTANIB. Retina, 2011, 31, 1028-1035.	1.0	94
384	INTRAVITREAL RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY WITH RECURRENT OR RESIDUAL EXUDATION. Retina, 2011, 31, 1589-1597.	1.0	30
385	INTRAVITREAL BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION. Retina, 2011, 31, 1856-1862.	1.0	46
386	INTRAVITREAL RANIBIZUMAB WITH OR WITHOUT PHOTODYNAMIC THERAPY FOR THE TREATMENT OF SYMPTOMATIC POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2011, 31, 1581-1588.	1.0	79
387	Preferred therapies for neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2011, 22, 199-204.	1.3	36
388	Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration. Current Drug Targets, 2011, 12, 149-172.	1.0	56
389	PROGNOSTI IMPLICATIONS OF PIGMENT EPITHELIAL DETACHMENT IN BEVACIZUMAB (AVASTIN)-TREATED EYES WITH AGE-RELATED MACULAR DEGENERATION AND CHOROIDAL NEOVASCULARIZATION. Retina, 2011, 31, 1812-1818.	1.0	30
390	Combined Treatment Modalities for Age Related Macular Degeneration. Current Drug Targets, 2011, 12, 182-189.	1.0	11
391	A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. Retina, 2011, 31, 1449-1469.	1.0	131
392	Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab. Graefe's Archive for Clinical and Experimental Ophthalmology, 2011, 249, 273-280.	1.0	9
393	Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Japanese Journal of Ophthalmology, 2011, 55, 39-44.	0.9	70
394	Negative correlation between aqueous vascular endothelial growth factor levels and axial length. Japanese Journal of Ophthalmology, 2011, 55, 401-404.	0.9	35
395	Microvascular Modifications in Diabetic Retinopathy. Current Diabetes Reports, 2011, 11, 253-264.	1.7	170
396	AltersabhÄngige Makuladegeneration. , 2011, , .		3
397	Intravitreal Bevacizumab for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Eighteen-Month Results of a Prospective Trial. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 615-621.	0.6	28
398	Vascular endothelial growth factor inhibition in uveitis: a systematic review. British Journal of Ophthalmology, 2011, 95, 162-165.	2.1	45

#	ARTICLE	IF	CITATIONS
399	Vitreous Web after Pars Plana Vitrectomy and Bevacizumab with Fluid-Air Exchange. <i>Seminars in Ophthalmology</i> , 2011, 26, 25-27.	0.8	7
400	One-Year Results of Intravitreal Ranibizumab with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy. <i>Ophthalmologica</i> , 2011, 226, 119-126.	1.0	26
401	Effects of Bevacizumab (Avastin®) on the Electroretinogram of Isolated Rat Retina. <i>Ophthalmic Research</i> , 2011, 46, 145-151.	1.0	2
402	Combined intravitreal bevacizumab with phacoemulsification in visually significant cataract and visually significant exudative maculopathy. <i>Oman Journal of Ophthalmology</i> , 2011, 4, 10.	0.2	1
403	Avastin Treatment Reduces Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity. <i>Current Eye Research</i> , 2012, 37, 624-629.	0.7	18
404	INTRAOcular BEVACIZUMAB LEVELS 24 HOURS AFTER INTRAVITREAL INJECTION IN A NORMAL EYE. <i>Retinal Cases and Brief Reports</i> , 2012, 6, 65-68.	0.3	2
405	HTRA1 in Age-Related Macular Degeneration. <i>Asia-Pacific Journal of Ophthalmology</i> , 2012, 1, 51-63.	1.3	12
406	Preferred therapies for neovascular age-related macular degeneration. <i>Current Opinion in Ophthalmology</i> , 2012, 23, 182-188.	1.3	43
407	An Update on Intravitreal Injections for Macular Diseases. <i>Asia-Pacific Journal of Ophthalmology</i> , 2012, 1, 43-50.	1.3	0
408	Diabetic Retinopathy: Current and New Treatment Options. <i>Current Diabetes Reviews</i> , 2012, 8, 32-41.	0.6	30
409	Functional and Anatomic Response of the Retina and the Choroid to Intravitreal Bevacizumab for Macular Edema. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 69-75.	0.6	7
410	Inhibitory Effects of SU5416, a Selective Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, on Experimental Corneal Neovascularization. <i>Ophthalmic Research</i> , 2012, 47, 13-18.	1.0	19
411	Focal Macular Electroretinograms after Intravitreal Injections of Bevacizumab for Age-Related Macular Degeneration. , 2012, 53, 4185.		14
412	Effect of Vitrectomy on Aqueous VEGF Concentration and Pharmacokinetics of Bevacizumab in Macaque Monkeys. , 2012, 53, 5877.		86
413	CHOROIDAL NEOVASCULARIZATION SECONDARY TO SORSBY FUNDUS DYSTROPHY TREATED WITH INTRAVITREAL BEVACIZUMAB. <i>Retinal Cases and Brief Reports</i> , 2012, 6, 193-196.	0.3	8
414	RETREATMENT WITH ANTI-“VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY BASED ON CHANGES IN VISUAL ACUITY AFTER INITIAL STABILIZATION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2012, 32, 1471-1479.	1.0	7
415	ASSOCIATION BETWEEN HIGH-RISK DISEASE LOCI AND RESPONSE TO ANTI-“VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2012, 32, 4-9.	1.0	56
416	Clinical and Electrophysiologic Outcome in Patients with Neovascular Glaucoma Treated with and without Bevacizumab. <i>European Journal of Ophthalmology</i> , 2012, 22, 563-574.	0.7	28



#	ARTICLE	IF	CITATIONS
417	INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CHOROIDAL NEVUS. <i>Retina</i> , 2012, 32, 60-67.	1.0	19
418	INTRAVITREAL BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH GOOD VISUAL ACUITY. <i>Retina</i> , 2012, 32, 1811-1820.	1.0	11
420	One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetate with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation. <i>Japanese Journal of Ophthalmology</i> , 2012, 56, 599-607.	0.9	4
421	Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: A retrospective study of 58 patients. <i>Journal Francais D'Ophtalmologie</i> , 2012, 35, 661-666.	0.2	11
422	Bevacizumab and ranibizumab for neovascular age-related macular degeneration: a treatment approach based on individual patient needs. <i>Canadian Journal of Ophthalmology</i> , 2012, 47, 165-169.	0.4	9
423	Assessment of Differential Pharmacodynamic Effects Using Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration. , 2012, 53, 1152.		20
424	Phacoemulsification with Intravitreal Bevacizumab Injection in Patients with Cataract and Coexisting Diabetic Retinopathy: Prospective Randomized Study. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 212-218.	0.6	16
425	Vascular endothelial growth factors in retinal and choroidal neovascular diseases. <i>Annals of Medicine</i> , 2012, 44, 1-17.	1.5	46
426	Risk Factors for Conversion to Neovascular Age-related Macular Degeneration Based on Longitudinal Morphologic and Visual Acuity Data. <i>Ophthalmology</i> , 2012, 119, 1432-1437.	2.5	17
427	Bevacizumab for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen: Clinical and Economic Impact. <i>American Journal of Ophthalmology</i> , 2012, 153, 468-473.e1.	1.7	71
428	Delay to Treatment and Visual Outcomes in Patients Treated With Anti-Vascular Endothelial Growth Factor for Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2012, 153, 678-686.e2.	1.7	119
429	Treatment Patterns for Neovascular Age-Related Macular Degeneration: Analysis of 284 380 Medicare Beneficiaries. <i>American Journal of Ophthalmology</i> , 2012, 153, 1116-1124.e1.	1.7	61
430	Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. <i>Pharmacogenomics</i> , 2012, 13, 1037-1053.	0.6	27
431	Uveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and Intravitreal Biologics for Ocular Inflammation. <i>American Journal of Ophthalmology</i> , 2012, 154, 429-435.e2.	1.7	15
432	Evaluation of Age-related Macular Degeneration With Optical Coherence Tomography. <i>Survey of Ophthalmology</i> , 2012, 57, 389-414.	1.7	230
433	Corneal Neovascularization: An Anti-VEGF Therapy Review. <i>Survey of Ophthalmology</i> , 2012, 57, 415-429.	1.7	304
434	Proteomic Analysis of the Aqueous Humor in Age-related Macular Degeneration (AMD) Patients. <i>Journal of Proteome Research</i> , 2012, 11, 4034-4043.	1.8	52
435	New Approach of Anti-VEGF Agents for Age-Related Macular Degeneration. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-7.	0.6	15

#	ARTICLE	IF	CITATIONS
436	Treatment of Neovascular Age Related Macular Degeneration. , 2012, , .		0
437	Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. <i>Clinical Ophthalmology</i> , 2012, 6, 1149.	0.9	21
438	Controlled Release of Bevacizumab Through Nanospheres for Extended Treatment of Age-Related Macular Degeneration. <i>Open Ophthalmology Journal</i> , 2012, 6, 54-58.	0.1	87
439	Promising Treatment Strategies for Neovascular AMD: Anti-VEGF Therapy. , 0, , .		0
440	Comparison of Two Doses of IVB and Prognostic Factor on Myopic CNV : 1-Year Outcome. <i>Journal of Korean Ophthalmological Society</i> , 2012, 53, 1807.	0.0	1
441	Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model. <i>Journal of Evaluation in Clinical Practice</i> , 2012, 18, 247-255.	0.9	36
442	Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. <i>Acta Ophthalmologica</i> , 2012, 90, 61-67.	0.6	32
443	Acute bacterial endophthalmitis after intravitreal bevacizumab injection: Case report and literature review. <i>Saudi Journal of Ophthalmology</i> , 2013, 27, 55-57.	0.3	6
444	The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 341-352.	1.9	79
445	Long-term Visual Outcome and Prognostic Factors After Intravitreal Ranibizumab Injections for Polypoidal Choroidal Vasculopathy. <i>American Journal of Ophthalmology</i> , 2013, 156, 652-660.e1.	1.7	80
446	Fixation stability as a goal in the treatment of macular disease. <i>Canadian Journal of Ophthalmology</i> , 2013, 48, 364-367.	0.4	20
447	Evaluation of the effects of resveratrol and bevacizumab on experimental corneal alkali burn. <i>Burns</i> , 2013, 39, 326-330.	1.1	12
448	An Updated Study of the Use of Bevacizumab in the Treatment of Patients with Prethreshold Retinopathy of Prematurity in Taiwan. <i>American Journal of Ophthalmology</i> , 2013, 155, 150-158.e1.	1.7	116
449	Combination Therapies for the Treatment of AMD. , 2013, , 247-261.		1
452	MYOCARDIAL INFARCTION AFTER INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS. <i>Retina</i> , 2013, 33, 920-927.	1.0	42
453	Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization. <i>Journal of Personalized Medicine</i> , 2013, 3, 40-69.	1.1	23
454	Bevacizumab Monotherapy Versus Combined Therapy with Photodynamic Therapy for Occult Choroidal Neovascularization in Age-Related Macular Degeneration. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1554.	0.0	0
455	A Case of Acute Anterior Uveitis Associated with HLA-B27 Positivity after Intravitreal Injection of Bevacizumab. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1945.	0.0	0



#	ARTICLE	IF	CITATIONS
456	Twelve-Month Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinal Angiomatous Proliferation. <i>Journal of Korean Ophthalmological Society</i> , 2013, 54, 1700.	0.0	5
457	Vitreous Web after Pars Plana Vitrectomy and Bevacizumab Injection. <i>Journal of Korean Ophthalmological Society</i> , 2014, 55, 780.	0.0	0
458	Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab. <i>Journal of Ophthalmology</i> , 2014, 2014, 1-7.	0.6	36
459	Comparison between Simultaneous Intracameral and Intravitreal Injection and Intravitreal Injection of Bevacizumab in Neovascular Glaucoma. <i>Journal of Korean Ophthalmological Society</i> , 2014, 55, 1039.	0.0	1
460	The Effects of Intravitreal Bevacizumab in Infectious and Noninfectious Uveitic Macular Edema. <i>Journal of Ophthalmology</i> , 2014, 2014, 1-6.	0.6	16
461	Treatment of macular edema in diabetic retinopathy: comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections. <i>Expert Review of Ophthalmology</i> , 2014, 9, 139-143.	0.3	11
462	Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. <i>British Journal of Ophthalmology</i> , 2014, 98, 1629-1635.	2.1	67
463	Switch from Intravitreal Ranibizumab to Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration: Clinical Comparison. <i>Ophthalmologica</i> , 2014, 232, 149-155.	1.0	8
464	Fc $\gamma$ 3 Receptor Upregulation Is Associated With Immune Complex Inflammation in the Mouse Retina and Early Age-Related Macular Degeneration. , 2014, 55, 247.		38
465	INTRAVITREAL ANTI-VEGF VASCULAR ENDOTHELIAL GROWTH FACTOR FOR CHOROIDAL NEOVASCULARIZATION IN OCULAR HISTOPLASMOSIS. <i>Retinal Cases and Brief Reports</i> , 2014, 8, 24-29.	0.3	11
466	COMPARISON OF INTRAVITREAL RANIBIZUMAB IN PHAKIC AND PSEUDOPHAKIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH GOOD BASELINE VISUAL ACUITY. <i>Retina</i> , 2014, 34, 853-859.	1.0	7
467	Intravitreal bevacizumab effects on VEGF levels in distant organs: an experimental study. <i>Cutaneous and Ocular Toxicology</i> , 2014, 33, 275-282.	0.5	8
468	Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical coherence tomography. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 889-897.	1.0	15
469	Pathologic Myopia. , 2014, , .		41
470	Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 331-337.	1.0	75
471	Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 152-164.	2.0	49
472	Photoreceptor transplantation into the mammalian retina. <i>Current Ophthalmology Reports</i> , 2014, 2, 91-99.	0.5	1
473	Factors influencing the exudation recurrence after cataract surgery in patients previously treated with anti-vascular endothelial growth factor for exudative age-related macular degeneration. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2014, 252, 1573-1579.	1.0	15

#	ARTICLE	IF	CITATIONS
474	Trophic factors in the pathogenesis and therapy for retinal degenerative diseases. Survey of Ophthalmology, 2014, 59, 134-165.	1.7	93
475	Intravitreal Anti-Vascular Endothelial Growth Factor for Submacular Hemorrhage from Choroidal Neovascularization. Ophthalmology, 2014, 121, 926-935.	2.5	69
476	Antivascular endothelial growth factor therapies for neovascular age-related macular degeneration: Search for the optimized treatment regimen. Taiwan Journal of Ophthalmology, 2014, 4, 3-8.	0.3	4
477	Neovascular Age-Related Macular Degeneration. Developments in Ophthalmology, 2016, 55, 125-136.	0.1	52
478	Pharmacogenetic Effect of Complement Factor H Gene Polymorphism in Response to the Initial Intravitreal Injection of Bevacizumab for Wet Age-Related Macular Degeneration. Ophthalmic Research, 2015, 54, 169-174.	1.0	15
479	Bevacizumab and Aflibercept Activate Platelets via FcγR1a. , 2015, 56, 8075.		17
480	22 anti-vascular endothelial growth factor (anti-VEGF) therapy Optical Coherence Tomography and Anti-Vascular Endothelial Growth Factor Therapy. , 2015, , .		0
481	Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Drug Design, Development and Therapy, 2015, 9, 5397.	2.0	55
482	Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity. Ophthalmology, 2015, 122, 1008-1015.	2.5	179
483	Evaluation of Intracameral Injection of Ranibizumab and Bevacizumab on the Corneal Endothelium by Scanning Electron Microscopy. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 100-105.	0.6	7
484	Effects of intravitreal injection of bevacizumab on nitric oxide levels. Eye, 2015, 29, 436-442.	1.1	5
485	Subfoveal choroidal thickness changes after intravitreal bevacizumab therapy for central serous chorioretinopathy. Arquivos Brasileiros De Oftalmologia, 2016, 79, 308-311.	0.2	7
486	Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment. PLoS ONE, 2016, 11, e0148019.	1.1	121
487	Anti-angiogenic effect of ALS-1023, an extract of <i>Melissa officinalis</i> L., on experimental choroidal neovascularization in mice. Clinical and Experimental Ophthalmology, 2016, 44, 43-51.	1.3	0
488	Self-recognition of recurrences among patients with exudative age-related macular degeneration. Australasian journal of optometry, The, 2016, 99, 56-60.	0.6	0
489	Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy. Eye, 2016, 30, 805-811.	1.1	29
490	A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Progress in Retinal and Eye Research, 2016, 50, 1-24.	7.3	284
491	Early clinical characteristics of bacterial endophthalmitis in retinopathy of prematurity after intravitreal bevacizumab injection: A case report. Experimental and Therapeutic Medicine, 2017, 13, 3563-3566.	0.8	20

#	ARTICLE	IF	CITATIONS
492	Relationship Between Visual Acuity and Retinal Thickness During Anti-vascular Endothelial Growth Factor Therapy for Retinal Diseases. <i>American Journal of Ophthalmology</i> , 2017, 180, 8-17.	1.7	60
493	One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2017, 237, 105-110.	1.0	11
494	Pluripotent stem cells and their utility in treating photoreceptor degenerations. <i>Progress in Brain Research</i> , 2017, 231, 191-223.	0.9	19
495	Pretreatment of RPE Cells with Lutein Can Mitigate Bevacizumab-Induced Increases in Angiogenin and bFGF. <i>Ophthalmic Research</i> , 2017, 57, 48-53.	1.0	7
496	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. <i>Progress in Retinal and Eye Research</i> , 2018, 65, 127-146.	7.3	205
497	Estimating Public and Patient Savings From Basic Research—A Study of Optical Coherence Tomography in Managing Antiangiogenic Therapy. <i>American Journal of Ophthalmology</i> , 2018, 185, 115-122.	1.7	35
498	Negative regulators of angiogenesis, ocular vascular homeostasis, and pathogenesis and treatment of exudative AMD. <i>Journal of Ophthalmic and Vision Research</i> , 2018, 13, 470.	0.7	21
499	Novel devices for studying acute and chronic mechanical stress in retinal pigment epithelial cells. <i>Lab on A Chip</i> , 2018, 18, 3413-3424.	3.1	15
500	The Effect of Avastin on Posterior Capsular Opacification after Phacoemulsification: A Randomized Controlled Trial Mitsugu. <i>Journal of Clinical Trials</i> , 2018, 08, .	0.1	0
501	Intravitreal injection of the synthetic peptide LyeTx I b, derived from a spider toxin, into the rabbit eye is safe and prevents neovascularization in a chorio-allantoic membrane model. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2018, 24, 31.	0.8	7
502	Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection. , 2018, 59, 5266.		25
503	Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization. <i>PLoS ONE</i> , 2018, 13, e0202436.	1.1	11
504	Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization. <i>Drug Delivery</i> , 2018, 25, 1372-1383.	2.5	70
505	Time trends, disease patterns and gender imbalance in the top 100 most cited articles in ophthalmology. <i>British Journal of Ophthalmology</i> , 2019, 103, 18-25.	2.1	21
506	Preclinical Evaluation of UDCA-Containing Oral Formulation in Mice for the Treatment of Wet Age-Related Macular Degeneration. <i>Pharmaceutics</i> , 2019, 11, 561.	2.0	9
507	Thermo-responsive hydrogel as an anti-VEGF drug delivery system to inhibit retinal angiogenesis in Rex rabbits. <i>Technology and Health Care</i> , 2019, 27, 153-163.	0.5	17
508	Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles. <i>Biomedical Microdevices</i> , 2019, 21, 46.	1.4	64
509	The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. <i>Survey of Ophthalmology</i> , 2019, 64, 707-719.	1.7	25

#	ARTICLE	IF	CITATIONS
510	Eye Diseases and Stem Cells. , 2019, , 598-607.		0
511	Analysis of the Clinical Profile and Management of Inflammatory Choroidal Neovascular Membranes in Uveitic Eyes: A Study from a Tertiary Referral Center. Ocular Immunology and Inflammation, 2019, 27, 424-434.	1.0	8
512	Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population. Ophthalmic Research, 2019, 61, 168-173.	1.0	12
513	Effect of elevation of vascular endothelial growth factor level on exacerbation of hemorrhage in mouse brain arteriovenous malformation. Journal of Neurosurgery, 2020, 132, 1566-1573.	0.9	27
514	Regenerative medicine as a novel strategy for AMD treatment: a review. Biomedical Physics and Engineering Express, 2020, 6, 012001.	0.6	2
515	Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians. Ophthalmology Retina, 2020, 4, 403-414.	1.2	25
516	Lipid Keratopathy: A Review of Pathophysiology, Differential Diagnosis, and Management. Ophthalmology and Therapy, 2020, 9, 833-852.	1.0	19
517	&lt;p&gt;Trends in Real-World Neovascular AMD Treatment Outcomes in the UK&lt;p&gt;. Clinical Ophthalmology, 2020, Volume 14, 3331-3342.	0.9	29
518	A systematic approach to evaluate practice-based process- and outcome data applied to the treatment of neovascular age-related macular degeneration. BMC Ophthalmology, 2020, 20, 21.	0.6	1
519	Drugs Used in Ophthalmology. , 2021, , 413-499.		0
520	The promising retinal optical coherence tomography biomarkers in common macular diseases: A brief summary of the literature. Alpha Psychiatry, 2021, , .	0.0	0
521	Choroidal Neovascularization. , 2021, , 271-293.		0
522	Association between retinal thickness variation and visual acuity change in neovascular age-related macular degeneration. Clinical and Experimental Ophthalmology, 2021, 49, 430-438.	1.3	3
523	Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes. PLoS ONE, 2021, 16, e0252006.	1.1	2
524	Endophthalmitis: a bibliographic review. International Ophthalmology, 2021, 41, 4151-4161.	0.6	7
525	The 100 most-cited papers on age-related macular degeneration: a bibliographic perspective. BMJ Open Ophthalmology, 2021, 6, e000823.	0.8	4
527	Protein Drug Delivery and Formulation Development. AAPS Advances in the Pharmaceutical Sciences Series, 2011, , 409-448.	0.2	4
528	Age-Related Macular Degeneration and Vision Impairment. , 2016, , 471-507.		1

#	ARTICLE	IF	CITATIONS
529	Ranibizumab: Phase III clinical trial results. <i>Ophthalmology Clinics of North America</i> , 2006, 19, 361-72.	1.8	229
530	INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH OR WITHOUT PRIOR TREATMENT WITH PHOTODYNAMIC THERAPY. <i>Retina</i> , 2010, 30, 85-92.	1.0	15
531	Chemoprevention of age-related macular regeneration (AMD) with rapamycin. <i>Aging</i> , 2012, 4, 375-376.	1.4	16
532	Ranibizumab in neovascular age-related macular degeneration. <i>Clinical Interventions in Aging</i> , 2006, 1, 451-466.	1.3	15
533	The Role of Steroids and NSAIDs in Prevention and Treatment of Postsurgical Cystoid Macular Edema. <i>Current Pharmaceutical Design</i> , 2019, 24, 4896-4902.	0.9	29
534	Common Variant in VEGFA and Response to Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration. <i>Current Molecular Medicine</i> , 2013, 13, 929-934.	0.6	36
535	Safety and Efficacy of Intravitreal Bevacizumab Followed by Pegaptanib Maintenance as a Treatment Regimen for Age-Related Macular Degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2006, 37, 446-454.	0.4	31
536	Treatment of Neovascular Age-Related Macular Degeneration with Pegaptanib and Boosting with Bevacizumab or Ranibizumab as Needed. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2008, 39, 294-298.	0.4	7
537	Ranibizumab for Exudative Age-Related Macular Degeneration in Eyes Previously Treated With Alternative Vascular Endothelial Growth Factor Inhibitors. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 182-189.	0.4	18
538	Computer-Assisted Image Processing for a Simulated Stereo Effect of Ocular Fundus and Fluorescein Angiography Photographs. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010, 41, 293-300.	0.4	2
539	Predictors of visual outcome in eyes with choroidal neovascularization secondary to age related macular degeneration treated with intravitreal bevacizumab monotherapy. <i>International Journal of Ophthalmology</i> , 2013, 6, 62-6.	0.5	24
540	Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits. <i>International Journal of Ophthalmology</i> , 2015, 8, 653-8.	0.5	22
541	Arg-Leu-Tyr-Glu Suppresses Retinal Endothelial Permeability and Choroidal Neovascularization by Inhibiting the VEGF Receptor 2 Signaling Pathway. <i>Biomolecules and Therapeutics</i> , 2019, 27, 474-483.	1.1	7
542	Batch-related sterile endophthalmitis following intravitreal injection of bevacizumab. <i>Indian Journal of Ophthalmology</i> , 2014, 62, 468.	0.5	15
543	Bevacizumab: Off-label use in ophthalmology. <i>Indian Journal of Ophthalmology</i> , 2007, 55, 417.	0.5	58
544	A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). <i>Indian Journal of Ophthalmology</i> , 2007, 55, 437.	0.5	29
545	Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. <i>Indian Journal of Ophthalmology</i> , 2007, 55, 451.	0.5	37
546	Stenotrophomonas maltophilia: An emerging entity for cluster endophthalmitis. <i>Indian Journal of Ophthalmology</i> , 2017, 65, 1166.	0.5	11

#	ARTICLE	IF	CITATIONS
547	Efficacy of intravitreal bevacizumab for the treatment of Zone I Type 1 retinopathy of prematurity. <i>Journal of Ophthalmic and Vision Research</i> , 2018, 13, 29.	0.7	8
548	Lamellar macular hole formation following intravitreal bevacizumab injection for choroidal neovascularization by age-related macular degeneration. <i>Oman Journal of Ophthalmology</i> , 2018, 11, 277.	0.2	2
552	Anti-VEGF Therapy as an Emerging Treatment for Diabetic Retinopathy. , 2008, , 401-422.		0
553	Surgical choroidal neovascular membrane removal in the era of anti-vascular endothelial growth factor agents. <i>Indian Journal of Ophthalmology</i> , 2009, 57, 146.	0.5	0
557	Tratamiento de la neovascularizaci3n coroidea en el miope magno con inyecci3n intrav4trea de antiangiog3nicos. , 2010, , 95-100.		0
559	Anti-VEGF en las lesiones polipoideas y la proliferaci3n angiomatosa de la retina. , 2010, , 69-79.		0
560	Neovascular age-related macular degeneration. , 2010, , 536-543.		0
561	Combined Therapies to Treat CNV in AMD: PDT + Anti-VEGF. , 0, , .		0
562	Intravitreal bevacizumab injection for management of macular edema in branch retinal vein occlusion. <i>Egyptian Retina Journal</i> , 2013, 1, 45.	0.2	0
563	Management of retinal diseases. <i>OA Case Reports</i> , 2013, 2, .	0.1	0
564	Choroidal Neovascularization. , 2014, , 211-230.		0
565	Anti-VEGF Therapy - Managing Challenging Case Scenarios. <i>Delhi Journal of Ophthalmology</i> , 2014, 25, 129-136.	0.0	1
566	Drug-induced ocular side effects. , 2015, , 47-343.		0
567	Macular disorders: study of demographic patterns and management trends. <i>Indian Journal of Clinical and Experimental Ophthalmology</i> , 2016, 2, 132.	0.1	0
568	Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study. <i>Digital Journal of Ophthalmology: DJO</i> , 2016, 22, 46-53.	0.2	6
569	Indocyanine Green Mediated Photothrombosis (IMP) with Intravitreal Bevacizumab (IVB) for Treatment of Choroidal Neovascular Membrane (CNV) due to ARMD. <i>Delhi Journal of Ophthalmology</i> , 2016, 26, 180-184.	0.0	0
570	6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome. <i>International Journal of Ophthalmology</i> , 2016, 9, 551-5.	0.5	1
572	Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 4993-5000.	0.8	15

#	ARTICLE	IF	CITATIONS
573	Introduction and Basic Concepts in Stem Cell Research and Therapy: The Facts and the Hype. Learning Materials in Biosciences, 2020, , 1-36.	0.2	0
574	Novel Therapeutic Strategies For Posterior Segment Neovascularization. , 2008, , 445-526.		0
575	Intravitreal bevacizumab: an analysis of the evidence. Clinical Ophthalmology, 2007, 1, 273-84.	0.9	8
576	Surgical removal of subfoveal choroidal neovascular membranes in older patients without age-related macular degeneration. Clinical Ophthalmology, 2007, 1, 157-65.	0.9	3
578	Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration. Core Evidence, 2008, 2, 273-94.	4.7	8
579	Delayed corneal epithelial healing after intravitreal bevacizumab: a clinical and experimental study. Journal of Ophthalmic and Vision Research, 2011, 6, 18-25.	0.7	8
580	Low-fluence photodynamic therapy combinations in the treatment of exudative age-related macular degeneration. International Journal of Ophthalmology, 2012, 5, 377-83.	0.5	1
581	Vascular endothelial growth factors and their inhibitors in ocular neovascular disorders. Journal of Ophthalmic and Vision Research, 2009, 4, 105-14.	0.7	12
582	Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration. Journal of Ophthalmic and Vision Research, 2008, 3, 95-101.	0.7	6
583	Two Different Doses of Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Associated with Age-related Macular Degeneration. Journal of Ophthalmic and Vision Research, 2008, 3, 102-7.	0.7	5
584	Indocyanine green mediated photothrombosis and high dose intravitreal bevacizumab as adjuvant therapy for isolated choroidal metastasis from breast cancer. Journal of Ophthalmic and Vision Research, 2012, 7, 332-40.	0.7	3
585	Specific inhibition of serine/arginine-rich protein kinase attenuates choroidal neovascularization. Molecular Vision, 2013, 19, 536-43.	1.1	9
587	Effects of three consecutive monthly intravitreal injection of ranibizumab for polypoidal choroidal vasculopathy in Korea. International Journal of Ophthalmology, 2015, 8, 315-20.	0.5	1
588	Teratogenic Effects of Intravitreal Injection of Bevacizumab in a Pregnant Rat Model. Iranian Journal of Pharmaceutical Research, 2017, 16, 670-676.	0.3	4
589	Resultados de vida real en el tratamiento de la degeneración macular asociada a la edad neovascular con terapia anti-VEGF. Análisis de 122 pacientes de un solo centro. Archivos De La Sociedad Espanola De Oftalmología, 2021, , .	0.1	0
590	The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage. BMC Ophthalmology, 2022, 22, 63.	0.6	10
591	Real-life results in treating neovascular age-related macular degeneration with anti-VEGF therapy. Analysis of 122 patients from a single centre. Archivos De La Sociedad Espanola De Oftalmología, 2021, 97, 191-197.	0.1	0
594	Effect of Alcohol on Vascular Endothelial Growth Factor Expression in Retinal Pigment Epithelium Cells and Angiogenesis. Journal of Retina, 2022, 7, 1-8.	0.1	0



#	ARTICLE	IF	CITATIONS
595	Review of Intraocular Inflammation After Antivascular Endothelial Growth Factor Agents. <i>International Ophthalmology Clinics</i> , 2022, 62, 35-47.	0.3	1
597	Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration. <i>Biomolecules</i> , 2022, 12, 1629.	1.8	20
598	Morphological and functional retinal changes in neovascular age-related macular degeneration treated with intravitreal bevacizumab. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 4376.	0.5	0